Product Images Fluticasone Propionate And Salmeterol Diskus
View Photos of Packaging, Labels & Appearance
- Remedy_Label - Remedy Label
- Fluticasone propionate chemical structure - fp sal spl graphic 01
- Salmeterol xinafoate chemical structure - fp sal spl graphic 02
- Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
- Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
- Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
- Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
- Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
- Figure A - fp sal spl graphic 08
- Figure B - fp sal spl graphic 09
- Figure C - fp sal spl graphic 10
- Figure D - fp sal spl graphic 11
- Figure E - fp sal spl graphic 12
- Figure F - fp sal spl graphic 13
- Figure G - fp sal spl graphic 14
- Figure H - fp sal spl graphic 15
Product Label Images
The following 16 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 70518-4346 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
This is a description of Fluticasone Propionate/Salmeterol inhalation powder with a strength of 100mcg/50mcg in 60 blister packs. It is intended for oral inhalation only and should be stored in a dry place away from direct heat or sunlight. The medication was repackaged by RemedyRepack Inc. in Indiana and the original manufacturer is Prasco Laboratories in Mason, Ohio. Keep the medication out of the reach of children and store it at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F).*
Fluticasone propionate chemical structure - fp sal spl graphic 01
Salmeterol xinafoate chemical structure - fp sal spl graphic 02
Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
This text shows data related to a study comparing the impact on FEV (Forced Expiratory Volume) of different medication regimens. Fluticasone propionate/salmeterol combination, fluticasone propionate alone, salmeterol alone, and placebo were administered to the subjects. The text also includes percentage changes in FEV over time.*
Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
This information shows the percentage change in FEV4 for different treatments over time. The data includes treatments with Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The measurements are taken on Day 1 and at Baseline for comparison.*
Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
This is an evaluation chart showing the % Change in Forced Expiratory Volume (FEV) relative to the Day 1 Baseline for different treatment groups. The treatments include Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The chart displays data for different time points from Day 1 to Week 12.*
Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
This is a table showing results of a study with Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily compared to Salmeterol 50 mcg twice daily and Placebo. The study measured FEV1 values over weeks, showing the effectiveness of the medications.*
Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
This text provides data on the comparison of the effects of Fluticasone propionate/salmeterol, Fluticasone propionate, and Placebo on baseline FEV. The study includes measurements at different time points and shows the number of participants for each group.*
Figure A - fp sal spl graphic 08
This text provides details about a medication called "Putiasone" paired with "Salmeterol DISKUS" for inhalation through a powder dosage form. The text mentions a "Mouthpiece" and "Lever" possibly related to the administration of the medication.*
Figure B - fp sal spl graphic 09
Figure C - fp sal spl graphic 10
Figure D - fp sal spl graphic 11
Figure E - fp sal spl graphic 12
Figure F - fp sal spl graphic 13
Figure G - fp sal spl graphic 14
Figure H - fp sal spl graphic 15
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
